Innovative research into the gene-editing tool targets influenza’s ability to replicate—stopping it in its tracks.

A live webcast of the presentation will be available on the "Events & Presentations" page in the Investors section of the ...

A new CRISPR breakthrough shows scientists can turn genes back on without cutting DNA, by removing chemical tags that act ...

Which genes are required for turning embryonic stem cells into brain cells, and what happens when this process goes wrong? In ...

A new CRISPR approach can control genes without cutting DNA, opening a safer path for treating genetic diseases. A newly ...

A sweeping genetic screen reveals how the brain is built and exposes a hidden gene behind a newly discovered childhood brain ...

The company does possess a lot of potential, with its approved gene-editing treatment Casgevy. Unfortunately, sales from that haven't exactly been soaring, and thus its financial performance has ...

CRISPR Therapeutics (CRSP) shares closed at US$53.77 on Friday, with recent returns mixed, including a 2.5% gain over the past day but a weaker pattern over the month and the past 3 months. See our ...

Four autoimmune patients treated to date demonstrate deep B-cell depletion sustained for at least 28 days; initial efficacy ...

Contrarius Investment Management, an investment management company, released its third-quarter investor letter for the ...

Explore how nanotechnology acts as the 'Convergence Engine' for AI materials discovery, CRISPR gene therapy delivery, and ...

CRISPR Therapeutics shares early autoimmune and lymphoma data for zugo-cel, showing strong responses, manageable safety, and expanded oncology plans.